Astrazeneca (AZN) Receivables - Net (2015 - 2025)

Astrazeneca (AZN) has reported Receivables - Net for 18 consecutive years, with $14.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 6.46% year-over-year to $14.1 billion; the TTM figure through Mar 2026 stood at $14.1 billion (up 6.46% YoY), while the FY2025 annual figure was $15.2 billion, up 17.0% from the prior year.
• Receivables - Net came in at $14.1 billion for Q1 2026 at Astrazeneca, down from $15.2 billion in the prior quarter.
• The five-year high for Receivables - Net was $15.2 billion in Q4 2025, with the low at $8.4 billion in Q4 2023.
• Average Receivables - Net over 5 years is $11.6 billion, with a median of $11.1 billion recorded in 2023.
• Across the five-year window, Receivables - Net jumped 74.97% in 2022 and decreased 20.09% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $10.5 billion in 2022, then fell by 20.09% to $8.4 billion in 2023, then jumped by 54.3% to $13.0 billion in 2024, then grew by 17.0% to $15.2 billion in 2025, then fell by 7.06% to $14.1 billion in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $14.1 billion, $15.2 billion, and $14.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.